Diagnosis and treatment of osteopenia

  title={Diagnosis and treatment of osteopenia},
  author={Gulay Karaguzel and Michael F. Holick},
  journal={Reviews in Endocrine and Metabolic Disorders},
  • G. KaraguzelM. Holick
  • Published 1 December 2010
  • Medicine, Biology
  • Reviews in Endocrine and Metabolic Disorders
Osteopenia is a term to define bone density that is not normal but also not as low as osteoporosis. By definition from the World Health Organization osteopenia is defined by bone densitometry as a T score −1 to −2.5. There are many causes for osteopenia including calcium and vitamin D deficiency and inactivity. Genetics plays an important role in a person’s bone mineral density and often Caucasian women with a thin body habitus who are premenopausal are found to have osteopenia. Correction of… 

A review on Osteoporosis and its Diagnosis.

A tool called FRAX to estimate the fracture risk which expresses the probability of hip or vertebra fracture in the next 10 years was developed and was tested on more than a million patients.

Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions

This review, which is based on a systematic appraisal of the current literature, provides current molecular and genetic opinions on osteoporosis and its medical treatment and offers evidence-based information to help researchers and clinicians with osteopOrosis assessment.

Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review

The role of bisphosphonate therapy for fracture risk reduction and increment in bone mineral density (BMD) in patients with oste Openia is highlighted by reviewing different national and international guidelines for treating osteopenia.

Nutritional Support and Physical Modalities for People with Osteoporosis: Current Opinion

This review comprises a systematic survey of the current literature on osteoporosis and its nonpharmacologic and nonsurgical treatment and provides clinicians and healthcare workers with evidence-based information on the assessment and management of osteoporeosis.


There is currently limited evidence regarding osteoporosis and osteopenia in premenopausal women, but the use of conservative strategies for co-managing secondary causes may have the potential to improve long-term management of these conditions.

Frequency of Osteopenia and its association with dietary factors among female population aged 18-60 years

Osteopenia is regarded as a bone condition whereby its is observed that the Bone Mineral Density (BMD) is less than that of the mean value. however, it is not as low as Osteoporosis. Unfortunately

Do Older Adults With Reduced Bone Mineral Density Benefit From Strength Training? A Critically Appraised Topic.

The findings indicate that strength training has a significant positive influence on BMD in older women (ie, postmenopausal) with osteoporosis or osteopenia, however, it is not recommended to only rely on strength training as the increase of BMD may not appear fast enough to reach the minimal desired values.

B Vitamins, Homocysteine and Bone Health

It is uncertain whether supplementation with B Vitamins, such as folate, Vitamin B1, and Vitamin B6, could decrease hip fracture incidence, but the results of further clinical trials should be awaited before a conclusion is drawn.

The Association Between the Concentration of Serum Magnesium and Postmenopausal Osteoporosis

Postmenopausal women with osteoporosis have a lower concentration of serum Mg, however, the association between the concentration of Serum Mg and osteopenia needs further confirmation.

Effects of a curcumin-based supplementation in asymptomatic subjects with low bone density: a preliminary 24-week supplement study.

This preliminary study suggests that a curcumin-based supplementation in combination with an appropriate lifestyle could be beneficial in the prevention and management of osteopenia.



Cochrane Review on exercise for preventing and treating osteoporosis in postmenopausal women.

The value of exercise as a means of preventing the loss of bone mass has become less and less controversial, but what type of exercise is really effective, which programme, for how long, and in which manner it should be implemented is still unclear.

Exercise for preventing and treating osteoporosis in postmenopausal women.

Aerobics, weight bearing and resistance exercises are all effective in increasing the BMD of the spine in postmenopausal women and walking is also effective on the hip.

Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures

A strategy to reduce overall fracture incidence will likely require lifestyle changes and a targeted effort to identify and develop treatment protocols for women with less severe low bone mass who are nonetheless at increased risk for future fractures.

Treatment of Osteoporosis with Parathyroid Hormone and Teriparatide

Parathyroid hormone and Teriparatide are relatively new for the treatment of osteoporosis and belong to the group of anabolic agents that demonstrated an increase in bone mineral density and a significant reduction in vertebral fractures in postmenopausal women with osteopOrosis when given for 18–24 months.

Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women

The lifetime health benefits and costs of alendronate therapy to prevent fracture in postmenopausal women with osteopenia are estimated from $70000 to $332000 per quality-adjusted life-year.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis.

Optimal Vitamin D Status for the Prevention and Treatment of Osteoporosis

Patients being treated for osteoporosis should be adequately supplemented with calcium and vitamin D to maximise the benefit of treatment, and should be aggressively treated with pharmacological doses of vitamin D.

The diagnosis of osteoporosis

Trabecular bone density in a two year controlled trial of peroral magnesium in osteoporosis.

Since magnesium regulates calcium transport, and magnesium replacement in magnesium-deficient postmenopausal patients resulted in unexpected improvement in documented osteoporosis, we investigated

Clinical practice. Osteopenia.

A 55-year-old asymptomatic woman, who is 5 years postmenopausal, is concerned about osteoporosis, since her mother had a hip fracture at the age of 70 years, and measurements of bone mineral density with the use of dual-energy x-ray absorptiometry show T scores consistent with osteopenia.